FDA Sets VORANIGO's Patent Extension Clock Ticking
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for VORANIGO, a human drug product, so its patent can be extended. This means the company behind VORANIGO gets extra time to protect their invention, helping them make money while keeping the drug available. If you’re involved in drug patents or development, this update is a key step in the process.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
VORANIGO Patent Extension Eligibility
The FDA has determined the regulatory review period for VORANIGO so the company may seek an extension of a patent that claims this human drug product. This gives the company extra time to protect its invention, which can help the company earn more while keeping the drug available.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in